All In MedTech

Device Trial Radar · NCT06190717

Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial

Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 304 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

304

Planned (sponsor's estimate)

Start

Feb 21, 2024

Primary completion

Feb 1, 2028

Study completion Feb 1, 2028

Sponsor

Lead sponsor
Sonavex, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Jan 5, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 84 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, multi-center, two-arm, randomized trial to quantify the performance of the EchoMark®/EchoSure® System for AVF diagnostic ultrasound when used under a protocol of biweekly use for assessing fistula maturation and reducing time to Clinical Maturation.

Conditions

  • Diabetes
  • End Stage Renal Disease

Interventions

  • EchoMark/EchoSureDevice

    Subjects assigned to the Diagnostic Arm will have the EchoMark implanted at the time of AVF creation. The subject will return every 2 weeks for a follow-up assessment to include an EchoSure scan until fistula maturation and/or permanent access use is achieved. The EchoSure scans are to be reviewed by the investigator(s) or delegated study staff and aid in the determination when a further assessment, including a physical exam, is required to determine cannulation clearance or if an intervention(s) may be required to prevent failure of fistula maturation. All physical exams will include assessing the fistula for bruit and thrill. The subject's medical history will be reviewed at each visit and will include all interventions, cannulation attempts, and adverse event reporting.

  • Standard of CareProcedure

    Subjects are assessed using standard of care per KDOQI guidelines, which includes a physical exam at the 2-week follow-up visit and at the 4-6-week follow-up visit. All follow-up visits will include an assessment of adverse events and medical history review to include all interventions, cannulation attempts, and laboratory results. If evaluation yields an abnormal finding, subjects will undergo a Duplex ultrasound assessment and treatment under the institution's standard of care. All SOC Arm subjects will be followed per the institution's standard of care until fistula maturation occurs and/or permanent access use is achieved but no more frequently than once per month.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Safety EndpointTime frame: 6 months
  2. Primary Effectiveness EndpointTime frame: 6 months

Locations

23 sites in 1 country. Site status is shown where the registry gives one.

  • Trinity Research Group

    Dothan, Alabama · Recruiting

  • Southwest Kidney Institute

    Phoenix, Arizona · Recruiting

  • AKDHC Medical Research Services

    Phoenix, Arizona · Recruiting

20 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.